The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition
NCT00686972
Terminated
This study is being conducted to evaluate changes in sugar, metabolism, heart function and changes in body composition as patients lose weight following bariatric surgery. The investigators will compare improvements of the above changes as a function of the four different types of bariatric surgery. The investigators believe the most beneficial and safest procedure will be the Roux-en-Y.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
06/01/2017
Locations: Johns Hopkins Bayview Medical Center, Baltimore, Maryland
Conditions: Bariatric Surgery
Register for Updates
Incretin Regulation of Insulin Secretion in Monogenic Diabetes
NCT01795144
Completed
The purpose of this study is to explore the mechanisms of metabolic control in monogenic diabetes patients treated with sulfonylurea medications.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/06/2017
Locations: University of Chicago, Chicago, Illinois
Conditions: Monogenic Diabetes
Register for Updates
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
NCT01098539
Completed
This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin. Subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately controlled on their current regimen of diet and exercise or their antidiabetic therapy of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic medications will be recruited into the study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2017
Locations: GSK Investigational Site, Birmingham, Alabama +217 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
NCT01128894
Completed
This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2017
Locations: GSK Investigational Site, Birmingham, Alabama +173 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
NCT00976391
Completed
This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/21/2016
Locations: GSK Investigational Site, Birmingham, Alabama +209 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
NCT01475734
Completed
This is a stepped glucose clamp study designed to investigate the effect of treatment with albiglutide on counter-regulatory hormone responses and recovery from hypoglycemia in subjects with Type 2 diabetes mellitus. A single dose of albiglutide or placebo will be given prior to a stepped hyper- and hypoglycemic clamp. The goal of this study is to demonstrate that albiglutide increases insulin secretion and decreases glucagon levels in a glucose-dependent manner.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
11/20/2016
Locations: GSK Investigational Site, Chula Vista, California
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Safety and Efficacy of Albiglutide in Type 2 Diabetes
NCT00849056
Completed
The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Alabaster, Alabama +330 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
NCT00849017
Completed
The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Alabaster, Alabama +261 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
NCT00839527
Completed
The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Alabaster, Alabama +357 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
NCT00838916
Completed
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Alabaster, Alabama +337 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
NCT00838903
Completed
The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Birmingham, Alabama +385 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Pharmacokinetics/Pharmacodynamics of Albiglutide
NCT01357889
Completed
The first part of the study includes a single dose treatment period to evaluate the pharmacokinetic bioequivalence of a subcutaneous injection of albiglutide from process 2 drug substance compared with process 3 drug substance. The second part of the treatment period will evaluate additional pharmacokinetic and pharmacodynamic parameters and safety and tolerability of repeat doses of albiglutide given weekly for 12 weeks from process 2 drug substance compared with process 3 drug substance. Subje... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Dothan, Alabama +29 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates